| 1 |
Which of the following best describes the concept of "beat perception" as it relates to the auditory capabilities of newborn infants?
|
The ability to vocalize in response to auditory stimuli. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
According to the research, what experimental method is used to differentiate beat perception from statistical learning in newborns?
|
Monitoring brain activity using EEG during auditory stimulation. |
|
we manipulated the isochrony of sound sequences in order to disentangle statistical learning from beat perception in sleeping newborn infants in an EEG experiment.
|
as previously done in adults and macaque monkeys.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does the mismatch response (MMR) in EEG studies indicate about newborns' auditory processing?
|
Ability to memorize and recall auditory sequences. |
|
/
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
What does the term "statistical learning" refer to in the context of auditory processing in newborns?
|
Development of fine motor skills in response to sound. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which condition in the EEG study did NOT result in a differentiation between beat and offbeat responses in newborns?
|
Silence condition. |
|
In EEG studies involving rhythm perception in newborns, a silence condition generally serves as a control or baseline.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
Which neural mechanism is thought to underlie the synchronization of movement to a beat?
|
Neural entrainment. |
|
Neural entrainment refers to the process by which neural oscillations synchronize with the periodicity of external rhythmic stimuli, such as a musical beat.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
How does beat perception in newborns relate to their later musical abilities?
|
It is fundamental for developing rhythmic coordination and timing. |
|
Beat perception in newborns is an early indicator of the ability to detect and process temporal patterns, which is crucial for developing rhythmic coordination and timing.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does an isochronous condition in an auditory study typically involve?
|
A consistent temporal interval between sounds. |
|
An isochronous condition in an auditory study involves sounds presented at regular, evenly spaced intervals in time.
|
A N
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What is the primary purpose of using EEG in studies of auditory processing in newborns?
|
To record brain responses to sounds. |
|
The primary purpose of using EEG (electroencephalography) in studies of auditory processing in newborns is to measure brain activity in response to auditory stimuli
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
Which auditory feature is NOT directly studied in the newborn auditory processing research?
|
Language comprehension. |
|
In newborn auditory processing research, language comprehension is not typically studied because newborns are not yet capable of understanding the meaning of language.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What term is used to describe the appearance of scientific credibility used in the marketing of unproven cell-based therapies?
|
Tokens of scientific legitimacy |
|
Tokens of scientific legitimacy refer to strategies used in the marketing of unproven cell-based therapies to give an impression of scientific credibility.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
According to the article, which of the following is NOT a recognized reporting mechanism for adverse effects from cell and gene therapies?
|
Consumer Protection Agencies |
|
umer protection agencies typically handle issues related to product safety and consumer rights but are not designated mechanisms for reporting medical adverse effects.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What ethical consideration is primarily challenged by direct-to-consumer marketing of unproven cell and gene therapies?
|
Informed consent processes |
|
Direct-to-consumer marketing of unproven cell and gene therapies often undermines the informed consent process. Patients may not fully understand the risks, benefits, or lack of scientific evidence supporting these treatments because such marketing can be misleading. This compromises their ability to make truly informed decisions about their healthcare.
|
Patients may not fully understand the risks, benefits, or lack of scientific evidence supporting these treatments because such marketing can be misleading. This compromises their ability to make truly informed decisions about their healthcare.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What key feature differentiates proven CGT products from unproven ones according to regulatory standards?
|
Pre-marketing authorization by regulatory bodies |
|
Proven cell and gene therapy (CGT) products undergo rigorous scientific evaluation and must receive pre-marketing authorization from regulatory bodies (e.g., the FDA, EMA, or TGA) before being made available to the public.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
Which of the following is a risk associated with unproven CGT products highlighted in the article?
|
Potential for serious health risks |
|
Unproven cell and gene therapy (CGT) products often come with significant risks, including the potential for serious health risks. These therapies have not undergone the rigorous scientific testing and regulatory approval processes required for proven therapies, so their safety and effectiveness are uncertain.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
Which of the following is NOT a typical characteristic of unproven CGT products as discussed in the article?
|
Approval by major regulatory agencies |
|
Unproven cell and gene therapy (CGT) products typically lack approval by major regulatory agencies, such as the FDA, EMA, or TGA.
|
These therapies have not gone through the rigorous evaluation processes required for regulatory approval, which ensures safety and efficacy.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
How do regulatory bodies like the FDA and EMA ensure the safety of CGT products?
|
By requiring rigorous pre-marketing clinical trials |
|
Regulatory bodies like the FDA (U.S.) and EMA (European Union) ensure the safety of cell and gene therapy (CGT) products primarily by requiring rigorous pre-marketing clinical trials.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What is the primary goal of the ISCT's position on cell and gene therapies as mentioned in the article?
|
To support evidence-based products and oppose unproven ones |
|
The ISCT (International Society for Cell & Gene Therapy) emphasizes the importance of supporting evidence-based products and opposing unproven therapies.
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What is a potential consequence for patients using unproven CGT products?
|
Risk of serious adverse effects |
|
One of the primary risks for patients using unproven cell and gene therapy (CGT) products is the risk of serious adverse effects.
|
Since these therapies have not undergone the rigorous testing and regulatory approval processes required for proven treatments, their safety is uncertain.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What role does the ISCT play in the context of cell and gene therapies?
|
It opposes the premature commercialization of unproven therapies. |
|
The ISCT (International Society for Cell & Gene Therapy) plays a key role in advocating for the safe and ethical development of cell and gene therapies. One of its main functions is to oppose the premature commercialization of unproven therapies.
|
It supports evidence-based practices and emphasizes the importance of rigorous scientific evaluation and regulatory oversight before therapies are made available to the public. This helps protect patients from potentially unsafe or ineffective treatments.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|